Using biomarkers to enrich studies too early in the drug-development process, especially for cancer drugs, can prematurely narrow the patient population and lead to drug failure, cautioned Mark Ratain, professor of medicine at the University of Chicago.
 
“Should biomarkers be used for eligibility criteria in Phase I/II studies? My answer is, ‘No,’” Ratain said during a presentation at the American Association for Cancer Research’s annual meeting in Los Angeles last month.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.